cellular-senescence
(2)
OneSkin
OneSkin is a San Francisco biotech and direct-to-consumer skincare company founded by four Brazilian women scientists who set out to slow skin aging at the molecular level. Its flagship OS-01 peptide - identified from a library of 900+ candidates using computational screening and tested on lab-grown human skin models - targets senescent 'zombie' cells that drive wrinkles, thinning and loss of firmness. The company sells topical 'supplements' for the face, eyes, body and sun protection, and frames skin not as a cosmetic surface but as the body's largest organ and a lever on overall healthspan.
Adam Freund
Adam Freund is the founder and CEO of Arda Therapeutics, a San Carlos biotech built on a simple, contrarian bet: many chronic diseases are caused by specific cells gone wrong, so the cure is to find and delete those cells while leaving healthy tissue intact. A molecular biologist with a Berkeley PhD and a Stanford postdoc, he spent seven years at Google-backed Calico Life Sciences, where he helped grow the company from roughly 15 to 200-plus people and started its most advanced anti-aging therapeutic program. In late 2021 he left to start Arda as a solo founder with a deck and a thesis, and by October 2024 had raised a $43M Series A led by a16z Bio + Health. His tools are single-cell sequencing to map disease cell-by-cell and antibodies to do the deleting.